Review Article

Hypertension: Open Access

Structural and Functional Cardiac Remodeling in Hypertension: Pathophysiology and Clinical Implications

Yusuf Solak[1], Macit Kalçık[2*], Abdullah Sarıhan[3], Oğuzhan Çelik[4], Mehmet Mustafa Yılmaz[1], Osman Karaarslan[1], Mucahit Yetim[2], Muhammet Cihat Çelik[1], Lütfü Bekar[2] and Yusuf Karavelioğlu[2]

[1]Department of Cardiology, Hitit University Erol Olçok Education and Research Hospital, Corum, Turkey.

[2]Department of Cardiology, Faculty of Medicine, Hitit University, Corum, Turkey.

[3]Department of Cardiology, Gediz State Hospital, Kütahya, Turkey.

[4]Department of Cardiology, Faculty of Medicine, Muğla Sıtkı Koçman University, Muğla, Turkey.

[*]Corresponding Author
Macit Kalcik, Department of Cardiology, Faculty of Medicine, Hitit University, Turkey.

Submitted: 2026, Mar 03; **Accepted:** 2026, Apr 20; **Published:** 2026, May 08

Citation: Solak, Y., Kalcik, M., Sarihan, A., Celik, O., Yilmaz, M. M., et al. (2026). Structural and Functional Cardiac Remodeling in Hypertension: Pathophysiology and Clinical Implications. *Hypertens OA, 2*(2), 01-07.

Abstract

Hypertension induces a broad spectrum of structural and functional alterations in the myocardium collectively defined as cardiac remodeling. Initially, these changes represent adaptive responses to sustained pressure overload aimed at preserving cardiac output through increased wall thickness and normalization of wall stress. However, persistent hemodynamic burden and neurohormonal activation lead to maladaptive remodeling characterized by left ventricular hypertrophy, interstitial fibrosis, microvascular dysfunction, and impaired diastolic relaxation. These structural and molecular alterations are closely linked to the development of heart failure with preserved ejection fraction, atrial fibrillation, and increased susceptibility to ischemia. Contemporary imaging modalities, including echocardiographic strain analysis and cardiac magnetic resonance, have improved the detection of subclinical remodeling and myocardial fibrosis, allowing earlier identification of patients at risk. Beyond mechanical stress, pathways such as the renin–angiotensin–aldosterone system, sympathetic activation, inflammation, and oxidative stress play critical roles in promoting hypertrophy and extracellular matrix expansion. Importantly, evidence suggests that targeted pharmacological interventions may attenuate or partially reverse these changes when initiated early. This narrative review summarizes the mechanisms underlying hypertensive cardiac remodeling and highlights their clinical implications, emphasizing the importance of early detection and therapeutic modulation in preventing progression to overt cardiovascular disease.

Keywords: Hypertension, Cardiac Remodeling, Left Ventricular Hypertrophy, Myocardial Fibrosis, Diastolic Dysfunction

1. Introduction

Hypertension remains one of the most prevalent cardiovascular risk factors worldwide and is a major determinant of morbidity and mortality due to its long-term effects on target organs, particularly the heart [1]. Chronic elevation of systemic arterial pressure imposes sustained mechanical stress on the myocardium, triggering structural and functional alterations collectively referred to as cardiac remodeling. Initially, these changes serve as adaptive mechanisms that allow the heart to maintain cardiac output in the presence of increased afterload. However, persistent exposure to pressure overload ultimately leads to maladaptive remodeling characterized by left ventricular hypertrophy (LVH), interstitial

fibrosis, and impaired myocardial relaxation [2].

Cardiac remodeling in hypertension is not limited to geometric changes in ventricular structure but also involves molecular, cellular, and electrophysiological modifications that influence myocardial performance and clinical outcomes. Over time, these alterations contribute to the transition from asymptomatic hypertensive heart disease to clinically overt conditions such as heart failure with preserved ejection fraction (HFpEF), atrial fibrillation, and increased susceptibility to ischemia [3]. Importantly, the presence of LVH has consistently been shown to predict adverse cardiovascular events independent of traditional risk factors, highlighting its significance as both a marker and mediator of disease progression [4].

Beyond structural hypertrophy, hypertensive remodeling encompasses changes in myocardial composition, including extracellular matrix expansion and microvascular dysfunction. These processes increase myocardial stiffness and reduce coronary reserve, thereby impairing both diastolic and systolic performance under stress conditions [5]. Understanding the mechanistic pathways underlying these changes is critical, as early identification and targeted therapeutic intervention may modify the trajectory of hypertensive heart disease and reduce long-term cardiovascular risk.

A comprehensive literature search was conducted to identify relevant studies addressing the mechanisms and clinical implications of cardiac remodeling in hypertension. Electronic databases including PubMed/MEDLINE, Scopus, and Web of Science were systematically searched from inception through February 2026. The search strategy incorporated combinations of the following keywords and Medical Subject Headings (MeSH): “hypertension”, “cardiac remodeling”, “left ventricular hypertrophy”, “myocardial fibrosis”, “diastolic dysfunction”, “hypertensive heart disease”, “RAAS”, “oxidative stress”, and “ventricular–vascular interaction”.

Only peer-reviewed articles published in English were considered. Preference was given to original research articles, clinical trials, and major review papers indexed in PubMed to ensure scientific validity. Reference lists of relevant articles were also manually screened to identify additional eligible studies. Duplicate publications, non-indexed sources, and studies lacking clear relevance to hypertensive cardiac remodeling were excluded.

The aim of this narrative review is to provide a comprehensive and integrative overview of cardiac remodeling in hypertension by linking underlying pathophysiological mechanisms with their clinical consequences. Specifically, this review seeks to summarize the hemodynamic, molecular, and structural processes that drive myocardial adaptation and maladaptation in hypertensive states, while highlighting their role in the development of functional impairment, arrhythmias, and heart failure.

In addition, it aims to outline the clinical relevance of detecting remodeling patterns through contemporary imaging and biomarkers, and to discuss the potential for therapeutic strategies to prevent or reverse these changes. By bridging mechanistic insights with clinical implications, this review intends to support improved risk stratification and management of patients with hypertensive heart disease.

2. Definition and Phenotypes of Hypertensive Cardiac Remodeling

Cardiac remodeling in hypertension refers to the spectrum of structural, functional, and electrophysiological alterations that occur in response to sustained pressure overload. Traditionally, the most recognized manifestation of hypertensive remodeling is left ventricular hypertrophy (LVH), which develops as an adaptive response aimed at normalizing wall stress in accordance with the principles of pressure–volume relationships [6]. This adaptation most commonly presents as concentric hypertrophy, characterized by increased wall thickness with relatively preserved chamber size. Over time, however, continued exposure to elevated afterload may lead to maladaptive changes including chamber dilation, increased myocardial stiffness, and progressive impairment in myocardial performance [7].

In addition to ventricular structural changes, hypertensive remodeling frequently involves the left atrium. Elevated filling pressures secondary to impaired ventricular relaxation promote left atrial enlargement, which is closely associated with the development of atrial fibrillation and diastolic dysfunction [8]. At the myocardial level, remodeling is also marked by expansion of the extracellular matrix through increased collagen deposition and reduced matrix degradation, contributing to interstitial fibrosis and increased ventricular stiffness [9].

Functionally, these structural alterations translate into impaired diastolic filling, often preceding detectable systolic dysfunction. Early stages of hypertensive heart disease are therefore typically characterized by preserved ejection fraction despite reduced myocardial compliance. As remodeling progresses, subtle systolic abnormalities may emerge, detectable through advanced imaging techniques such as strain analysis even when conventional measures remain within normal limits [10].

Collectively, these phenotypic changes reflect the transition from adaptive myocardial compensation to a pathophysiological state associated with increased cardiovascular risk. The major structural and functional components of hypertensive cardiac remodeling and their clinical relevance are summarized in Table 1.

Remodeling Component	Structural Changes	Functional Impact	Clinical Relevance
Left Ventricle	Concentric hypertrophy, increased wall thickness	Impaired relaxation	Diastolic dysfunction
Left Atrium	Chamber enlargement	Reduced compliance	Atrial fibrillation risk
Myocardium	Interstitial fibrosis	Increased stiffness	HFpEF development
Microvasculature	Rarefaction	Reduced perfusion reserve	Ischemia without CAD
Extracellular Matrix	Collagen accumulation	Reduced elasticity	Elevated filling pressures
Abbreviations: HFpEF: Heart Failure with Preserved Ejection Fraction; CAD: Coronary Artery Disease			

Table 1: Structural and Functional Features of Hypertensive Cardiac Remodeling

3. Hemodynamic Drivers of Remodeling

The development of cardiac remodeling in hypertension is primarily driven by chronic hemodynamic stress imposed on the myocardium. Sustained pressure overload increases left ventricular wall stress, prompting structural adaptation in accordance with the Law of Laplace. This results in concentric hypertrophy, which initially serves to normalize wall tension and preserve systolic function. However, prolonged exposure to elevated afterload leads to progressive myocardial stiffening and impaired relaxation, marking the transition from adaptive compensation to maladaptive remodeling [11].

Beyond mechanical load, neurohormonal activation plays a central role in shaping the remodeling process. Hypertension is associated with persistent stimulation of the renin–angiotensin–aldosterone system (RAAS) and heightened sympathetic nervous system activity. These pathways contribute not only to vasoconstriction and sodium retention but also exert direct trophic effects on cardiomyocytes and fibroblasts, promoting hypertrophy and extracellular matrix expansion [12]. Angiotensin II, in particular, has been shown to stimulate myocardial growth and fibrosis independent of its hemodynamic effects.

The interaction between the left ventricle and the arterial system further amplifies remodeling. Increased arterial stiffness, a common feature of long-standing hypertension, augments pulse wave reflection and systolic load. This phenomenon increases myocardial oxygen demand and exacerbates ventricular stress, thereby accelerating structural and functional deterioration [13]. Such ventricular–vascular coupling abnormalities are increasingly recognized as key contributors to the progression of hypertensive heart disease and its clinical manifestations, including diastolic dysfunction and heart failure.

4. Cellular and Molecular Mechanisms

At the cellular level, hypertensive cardiac remodeling is characterized by coordinated changes involving cardiomyocytes, fibroblasts, vascular cells, and the extracellular matrix. Cardiomyocyte hypertrophy represents a central adaptive response to chronic pressure overload. This process is mediated through mechanotransduction pathways that activate intracellular signaling cascades leading to sarcomeric reorganization and re-expression of fetal gene programs. While initially compensatory, sustained hypertrophic signaling eventually contributes to metabolic inefficiency and impaired contractile performance [14].

In parallel, activation of cardiac fibroblasts promotes extracellular matrix remodeling through increased collagen synthesis and reduced degradation. This imbalance results in interstitial and perivascular fibrosis, which plays a pivotal role in increasing myocardial stiffness and impairing ventricular relaxation. The activity of matrix metalloproteinases (MMPs) and their tissue inhibitors becomes dysregulated in hypertension, further contributing to structural disorganization of the myocardial interstitium [15].

Inflammatory signaling is also increasingly recognized as a contributor to hypertensive remodeling. Low-grade chronic inflammation promotes fibroblast activation and enhances extracellular matrix deposition through cytokine-mediated pathways. In addition, oxidative stress generated by reactive oxygen species amplifies these processes by altering cellular signaling and promoting endothelial dysfunction [16]. Microvascular rarefaction and impaired nitric oxide bioavailability further compromise myocardial perfusion, creating a substrate for progressive structural and functional deterioration [17]. The principal molecular and pathophysiological mechanisms driving hypertensive cardiac remodeling are outlined in Table 2.

Mechanism	Primary Pathway	Cellular Effect	Structural Outcome
Pressure Overload	Increased afterload	Cardiomyocyte hypertrophy	LV wall thickening
RAAS Activation	Angiotensin II, Aldosterone	Fibroblast activation	Myocardial fibrosis
Sympathetic Activation	β-adrenergic signaling	Calcium dysregulation	Contractile impairment
Inflammation	Cytokine signaling	Immune cell infiltration	Matrix expansion
Oxidative Stress	ROS generation	Mitochondrial dysfunction	Endothelial damage
Abbreviations: RAAS: Renin–Angiotensin–Aldosterone System; ROS: Reactive Oxygen Species; LV: Left Ventricle			

Table 2: Key Mechanisms Contributing to Hypertensive Cardiac Remodeling

5. Role of Neurohormonal Pathways

Neurohormonal activation plays a central role in the initiation and progression of cardiac remodeling in hypertension, extending beyond purely hemodynamic stress. Among these systems, the renin–angiotensin–aldosterone system (RAAS) is particularly influential. Angiotensin II exerts direct effects on cardiomyocytes and fibroblasts, promoting hypertrophic growth and stimulating collagen synthesis within the myocardial interstitium. These actions occur independently of blood pressure elevation and contribute to increased ventricular stiffness and adverse structural remodeling [18].

Aldosterone further amplifies these effects by enhancing sodium retention, vascular inflammation, and myocardial fibrosis. Mineralocorticoid receptor activation has been shown to promote extracellular matrix expansion and impair diastolic function through direct myocardial actions, thereby linking hormonal dysregulation to structural cardiac changes [19]. In parallel, heightened sympathetic nervous system activity contributes to remodeling through chronic β-adrenergic stimulation, which alters calcium handling and promotes cardiomyocyte apoptosis over time [20].

Counter-regulatory mechanisms also exist within this neurohormonal framework. The natriuretic peptide system, including atrial and B-type natriuretic peptides, acts to mitigate hypertrophic and fibrotic signaling by promoting vasodilation, natriuresis, and inhibition of fibroblast activity. However, in chronic hypertension, these protective pathways are often insufficient to counterbalance persistent RAAS and sympathetic activation [21]. The net effect is a shift toward progressive myocardial remodeling and functional decline.

6. Imaging Assessment of Cardiac Remodeling

Accurate evaluation of cardiac remodeling in hypertension relies heavily on non-invasive imaging techniques that enable detailed assessment of structural and functional alterations. Echocardiography remains the most widely used modality in clinical practice due to its accessibility and ability to quantify left ventricular mass, geometry, and diastolic function. Parameters such as left ventricular mass index and relative wall thickness allow classification of remodeling patterns, while Doppler-based indices provide insight into ventricular filling pressures and relaxation abnormalities [22].

More advanced echocardiographic techniques, including speckle-tracking strain imaging, have enhanced the detection of subclinical myocardial dysfunction. Global longitudinal strain, in particular, has emerged as a sensitive marker of early systolic impairment even in patients with preserved ejection fraction. These subtle functional changes often precede overt structural abnormalities and carry prognostic significance in hypertensive populations [23].

Cardiac magnetic resonance imaging (MRI) offers superior spatial resolution and tissue characterization capabilities, enabling precise quantification of ventricular mass and detection of myocardial fibrosis. Techniques such as late gadolinium enhancement and T1 mapping allow differentiation between focal and diffuse fibrotic processes, providing insight into the extent of myocardial remodeling beyond conventional measurements [24]. Such imaging biomarkers have improved the understanding of disease progression and may contribute to risk stratification in hypertensive heart disease. The key imaging modalities used in the evaluation of hypertensive cardiac remodeling are summarized in Table 3.

Imaging Technique	Parameter Assessed	Clinical Utility	Added Value
Echocardiography	LV mass, geometry	Routine evaluation	Widely accessible
Doppler Imaging	Diastolic function	Filling pressure estimation	Early dysfunction detection
Speckle Tracking	Global longitudinal strain	Subclinical systolic dysfunction	Prognostic value
Cardiac MRI	Tissue characterization	Fibrosis detection	High precision
T1 Mapping	Diffuse fibrosis	Quantitative assessment	Early remodeling detection
Abbreviations: LV: Left Ventricle; MRI: Magnetic Resonance Imaging			

Table 3: Imaging Modalities in the Assessment of Hypertensive Remodeling

7. Clinical Implications

The structural and functional alterations that define hypertensive cardiac remodeling have substantial clinical consequences, influencing both the development and progression of cardiovascular disease. One of the most prominent outcomes is the transition toward heart failure, particularly heart failure with preserved ejection fraction (HFpEF). Increased myocardial stiffness resulting from hypertrophy and fibrosis impairs ventricular relaxation, leading to elevated filling pressures despite preserved systolic performance [25]. Over time, persistent remodeling may also contribute to subtle systolic dysfunction and eventual progression toward reduced ejection fraction in selected patients.

Hypertensive remodeling also creates a substrate for arrhythmogenesis. Left atrial enlargement and interstitial fibrosis disrupt normal electrical conduction, significantly increasing the risk of atrial fibrillation. In addition, structural heterogeneity within the ventricular myocardium may promote ventricular arrhythmias by altering conduction pathways and repolarization dynamics [26].

Furthermore, microvascular dysfunction associated with hypertensive remodeling reduces coronary flow reserve,

increasing susceptibility to myocardial ischemia even in the absence of obstructive coronary artery disease. This imbalance between myocardial oxygen supply and demand may contribute to symptoms such as exertional dyspnea and chest discomfort, and has been linked to adverse outcomes in hypertensive populations [27]. The presence and severity of remodeling therefore carry important prognostic implications, underscoring the need for early identification and targeted management.

8. Therapeutic Modulation of Remodeling

The recognition that cardiac remodeling in hypertension is not solely a consequence of pressure overload but also driven by neurohormonal and molecular mechanisms has important therapeutic implications. Effective blood pressure control remains the cornerstone of preventing and attenuating structural cardiac changes. Early intervention has been shown to limit the progression of left ventricular hypertrophy and improve diastolic function, whereas delayed treatment is often associated with incomplete reversal of myocardial alterations [28].

Pharmacologic therapies targeting neurohormonal pathways have demonstrated significant benefits in modulating remodeling. Inhibition of the renin–angiotensin–aldosterone system through angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been shown to promote regression of left ventricular hypertrophy and reduce myocardial fibrosis. These effects extend beyond blood pressure reduction and are attributed to direct myocardial actions on cellular growth and extracellular matrix turnover [29]. Similarly, mineralocorticoid receptor antagonists have been associated with improvements in myocardial stiffness and structural remodeling by limiting aldosterone-mediated fibrotic signaling [30].

More recently, emerging therapies have shown potential in influencing hypertensive remodeling through novel mechanisms. Agents such as sodium–glucose cotransporter 2 inhibitors appear to exert beneficial cardiovascular effects that include reductions in ventricular mass and improvements in myocardial energetics, although their precise mechanisms remain under investigation [31]. These findings highlight the evolving therapeutic landscape and underscore the possibility that structural cardiac changes in hypertension may be at least partially reversible with targeted treatment strategies.

9. Future Directions

Advances in the understanding of hypertensive cardiac remodeling have highlighted the need for more individualized approaches to risk assessment and management. Traditional evaluation based primarily on blood pressure levels may fail to capture the heterogeneity in myocardial response among patients. Emerging evidence suggests that genetic susceptibility and variability in molecular signaling pathways may influence the degree and pattern of remodeling, thereby contributing to differences in clinical outcomes [32].

Biomarker-guided strategies represent another promising area of development in the assessment of hypertensive cardiac remodeling. Circulating markers reflecting myocardial stress, fibrosis, and inflammation may provide additional insight into early structural alterations before overt dysfunction becomes clinically apparent. For instance, biomarkers associated with myocardial stretch, extracellular matrix turnover, and inflammatory activation have been linked to subclinical remodeling processes and may help identify patients in whom structural changes are already underway despite preserved ventricular function.

Integration of such biomarkers with imaging findings could enhance risk stratification by allowing a more comprehensive evaluation of both structural and biological disease activity. This combined approach may facilitate earlier intervention in patients at higher risk of progression and support more individualized monitoring strategies over time [33].

In parallel, advances in imaging technology and data analysis are expected to refine the detection and monitoring of hypertensive cardiac remodeling. The application of artificial intelligence to echocardiographic and cardiac magnetic resonance datasets has shown potential in identifying subtle structural and functional abnormalities that may not be evident through conventional analysis [34]. These innovations may facilitate more precise characterization of disease trajectories and support the development of targeted therapeutic strategies.

10. Conclusion

Cardiac remodeling represents a central pathophysiological consequence of chronic hypertension, reflecting the cumulative impact of sustained mechanical stress, neurohormonal activation, and molecular alterations within the myocardium. What begins as an adaptive response aimed at maintaining cardiac performance ultimately evolves into maladaptive structural and functional changes that increase the risk of heart failure, arrhythmias, and ischemic complications. The presence of left ventricular hypertrophy, myocardial fibrosis, and diastolic dysfunction serves not only as a marker of disease severity but also as an independent predictor of adverse cardiovascular outcomes.

Advances in imaging and biomarker assessment have improved the ability to detect early remodeling and monitor its progression, while therapeutic strategies targeting neurohormonal pathways have demonstrated potential in promoting regression of structural changes. Importantly, emerging treatment approaches suggest that remodeling may be at least partially reversible when addressed at earlier stages of disease. A comprehensive understanding of the mechanisms and clinical implications of hypertensive cardiac remodeling is therefore essential for improving risk stratification and guiding targeted interventions aimed at modifying disease trajectory and reducing long-term cardiovascular burden.

References

1. Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature reviews*

nephrology, 16(4), 223-237.
2. Díez, J. (2007). Mechanisms of cardiac fibrosis in hypertension. *The Journal of Clinical Hypertension, 9*(7), 546-550.
3. Drazner, M. H. (2011). The progression of hypertensive heart disease. *Circulation, 123*(3), 327-334.
4. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *New England Journal of Medicine, 322*(22), 1561-1566.
5. Hein, S., Arnon, E., Kostin, S., Schönburg, M., Elsässer, A., Polyakova, V., ... & Schaper, J. (2003). Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. *Circulation, 107*(7), 984-991.
6. Ganau, A., Devereux, R. B., Roman, M. J., De Simone, G., Pickering, T. G., Saba, P. S., ... & Laragh, J. H. (1992). Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. *Journal of the American College of Cardiology, 19*(7), 1550-1558.
7. Verdecchia, P., Schillaci, G., Borgioni, C., Ciucci, A., Gattobigio, R., Zampi, I., ... & Porcellati, C. (1996). Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. *The American journal of cardiology, 78*(2), 197-202.
8. Tsang, T. S., Barnes, M. E., Gersh, B. J., Bailey, K. R., & Seward, J. B. (2002). Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *The American journal of cardiology, 90*(12), 1284-1289.
9. Weber, K. T., & Brilla, C. G. (1991). Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. *Circulation, 83*(6), 1849-1865.
10. Kuznetsova, T., Herbots, L., Richart, T., D'hooge, J., Thijs, L., Fagard, R. H., ... & Staessen, J. A. (2008). Left ventricular strain and strain rate in a general population. *European heart journal, 29*(16), 2014-2023.
11. Grossman, W., Jones, D., & Mclaurin, L. P. (1975). Wall stress and patterns of hypertrophy in the human left ventricle. *The Journal of clinical investigation, 56*(1), 56-64.
12. Schmieder, R. E. (2010). End organ damage in hypertension. *Deutsches Ärzteblatt International, 107*(49), 866.
13. Safar, M. E., & London, G. M. (1987). Arterial and venous compliance in sustained essential hypertension. *Hypertension, 10*(2), 133-139.
14. Frey, N., & Olson, E. N. (2003). Cardiac hypertrophy: the good, the bad, and the ugly. *Annual review of physiology, 65*(1), 45-79.
15. Spinale, F. G. (2002). Matrix metalloproteinases: regulation and dysregulation in the failing heart. *Circulation research, 90*(5), 520-530.
16. Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., & Schiffrin, E. L. (2002). Spironolactone improves angiotensin-induced vascular changes and oxidative stress. *Hypertension, 40*(4), 504-510.
17. Schiffrin, E. L. (2004). Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment.
18. Mehta, P. K., & Griendling, K. K. (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *American Journal of Physiology-Cell Physiology, 292*(1), C82-C97.
19. Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A., ... & Delyani, J. A. (2002). Aldosterone induces a vascular inflammatory phenotype in the rat heart. *American journal of physiology-Heart and circulatory physiology, 283*(5), H1802-H1810.
20. Esler, M. (2014). Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. *Hypertension, 63*(3), e25-e32.
21. Levin, E. R., Gardner, D. G., & Samson, W. K. (1998). Natriuretic peptides. *New England journal of medicine, 339*(5), 321-328.
22. Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., ... & Stewart, W. (2006). Recommendations for chamber quantification. *European journal of echocardiography, 7*(2), 79-108.
23. Yingchoncharoen, T., Agarwal, S., Popović, Z. B., & Marwick, T. H. (2013). Normal ranges of left ventricular strain: a meta-analysis. *Journal of the American Society of Echocardiography, 26*(2), 185-191.
24. Treibel, T. A., White, S. K., Sado, D., Zemrak, F., Banypersad, S. M., Flett, A., ... & Moon, J. (2013). Interstitial expansion in pressure overload left ventricular hypertrophy. *Journal of Cardiovascular Magnetic Resonance, 15*, O92.
25. Zile, M. R., & Brutsaert, D. L. (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. *Circulation, 105*(11), 1387-1393.
26. Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998). Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *The American journal of cardiology, 82*(7), 2N-9N.
27. Camici, P. G., & Crea, F. (2007). Coronary microvascular dysfunction. *The New England Journal of Medicine, 356*(8), 830–840.
28. Dahlöf, B., Pennert, K., & Hansson, L. (1992). Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. *American Journal of Hypertension, 5*(2), 95–110.
29. Dahlöf, B., Pennert, K., & Hansson, L. (1992). Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies.
30. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., ... & Wittes, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *New England Journal of Medicine, 341*(10), 709-717.
31. Verma, S., & McMurray, J. J. (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. *Diabetologia, 61*(10), 2108-2117.

32. Vasan, R. S. (2003). Cardiac function and obesity. *Heart, 89*(10), 1127-1129.
33. Braunwald, E. (2008). Biomarkers in heart failure. *New England Journal of Medicine, 358*(20), 2148-2159.
34. Dey, D., Slomka, P. J., Leeson, P., Comaniciu, D., Shrestha, S., Sengupta, P. P., & Marwick, T. H. (2019). Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. *Journal of the American College of Cardiology, 73*(11), 1317-1335.